

Dr. Reddy's Laboratories Ltd
8-2-337, Road No. 3 – Banjara Hills
Hyderabad – 500 034, AP, India
Tel. +91 40 4900 2900
Fax + 91 40 4900 2999
www.drreddys.com

August 31, 2011

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai - 400 001
Fax Nos.: 022-22723121 / 22723719
26598238

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/

Scrip Code : 500124 / 934809

Scrip Code:DRREDDY-EQ / N1


Dear Sirs,

Sub: Press Release

Please find enclosed a Press Release titled "Dr. Reddy's announces settlement of Lipitor® (atorvastatin) ANDA litigation with Pfizer".

Kindly arrange to disseminate and display the same on your Notice Board for the purpose of information.

With regards,



Kedar Upadhye
Head - Investor Relations

Encl: as above

CC : New York Stock Exchange Inc.


DR. REDDY'S LABORATORIES LTD.
Global Generics-India
7-1-27, Ameerpet,
Hyderabad-500 016. A.P., India.

Press Release



Dr. Reddy's announces settlement of Lipitor® (atorvastatin) ANDA litigation with Pfizer

Hyderabad, India, August 30, 2011:

Dr Reddy's Laboratories (NYSE: RDY) announced today that it has entered into a settlement agreement with Pfizer which will resolve litigation related to Lipitor® Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, known generically as Atorvastatin Calcium tablets. The terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

Trademarks

Lipitor® is a registered Trademark of Pfizer

About Dr. Reddy's

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - *Pharmaceutical Services and Active Ingredients*, *Global Generics* and *Proprietary Products* – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

For more information please contact:

Investors and Financial Analysts:

Kedar Upadhye at kedar@drreddys.com /+91-40-66834297 | Raghavender R at raghavenderr@drreddys.com /+91-40-66511529

Milan Kalawadia (North America) at mkalawadia@drreddys.com or at 908-203-4931

Media:

S Rajan at rajans@drreddys.com or on +91-40-66511725.

Dr. Reddy's Laboratories Ltd.
Global Generics-India
7-1-27, Ameerpet,
Hyderabad-500 016, A.P., India.